Several brokerages have updated their recommendations and price targets on shares of Aura Biosciences (NASDAQ: AURA) in the last few weeks:
- 10/18/2024 – Aura Biosciences had its “buy” rating reaffirmed by analysts at Cowen Inc.
- 10/18/2024 – Aura Biosciences had its price target raised by analysts at Scotiabank from $20.00 to $23.00. They now have a “sector outperform” rating on the stock.
- 10/18/2024 – Aura Biosciences had its price target raised by analysts at BTIG Research from $21.00 to $24.00. They now have a “buy” rating on the stock.
- 10/18/2024 – Aura Biosciences had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a “buy” rating on the stock.
- 9/16/2024 – Aura Biosciences was upgraded by analysts at Evercore ISI to a “strong-buy” rating.
- 9/13/2024 – Aura Biosciences had its price target raised by analysts at JMP Securities from $19.00 to $23.00. They now have a “market outperform” rating on the stock.
- 9/13/2024 – Aura Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
- 9/9/2024 – Aura Biosciences was upgraded by analysts at Lifesci Capital to a “strong-buy” rating.
- 8/28/2024 – Aura Biosciences had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $19.00 price target on the stock.
Aura Biosciences Stock Performance
Shares of AURA traded down $0.18 during mid-day trading on Wednesday, reaching $11.21. 3,590 shares of the company’s stock traded hands, compared to its average volume of 175,699. The business’s 50-day moving average price is $8.80 and its 200-day moving average price is $8.13. The stock has a market capitalization of $555.38 million, a P/E ratio of -6.03 and a beta of 0.37. Aura Biosciences, Inc. has a 12 month low of $5.99 and a 12 month high of $12.38.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04. Equities research analysts anticipate that Aura Biosciences, Inc. will post -1.7 EPS for the current year.
Insider Activity at Aura Biosciences
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of AURA. Long Focus Capital Management LLC raised its position in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after purchasing an additional 561,766 shares during the last quarter. Levin Capital Strategies L.P. raised its position in shares of Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after acquiring an additional 216,266 shares in the last quarter. Regency Capital Management Inc. DE raised its position in shares of Aura Biosciences by 11.4% in the 1st quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock worth $6,163,000 after acquiring an additional 80,162 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Aura Biosciences by 51.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after acquiring an additional 48,549 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Aura Biosciences by 20.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after acquiring an additional 41,711 shares in the last quarter. 96.75% of the stock is owned by institutional investors.
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
See Also
- Five stocks we like better than Aura Biosciences
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is MarketRankā¢? How to Use it
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Best Stocks Under $5.00
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Aura Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.